一种用于胆道癌的新预后指标：ABIC评分。
A New Prognostic Indicator for Biliary Tract Cancers: The ABIC Score.
作者信息
Bayram Doğan, Bal Öznur, Karaman Kemal, Bardakçı Murat, Demirtaş Esmer Derya, Seven İsmet, Sekmek Serhat, Perkin Perihan, Köş Fahriye Tuğba, Algın Efnan, Uncu Doğan
机构信息
Department of Medical Oncology, Ankara City Hospital, 06800 Ankara, Turkey.
Department of Medical Oncology, University of Health Sciences, Ankara City Hospital, 06800 Ankara, Turkey.
出版信息
Curr Oncol. 2025 Mar 28;32(4):200. doi: 10.3390/curroncol32040200.
INTRODUCTION
Biliary tract cancers (BTC) comprise a heterogeneous group of malignancies, including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The main determinants of prognosis in BTC are the stage of the disease and the eligibility for curative treatment. Additionally, liver functional capacity is also one of the factors influencing survival in biliary tract cancers. The age-bilirubin-INR-creatinine (ABIC) score has been previously shown to predict prognosis in hepatic diseases. The aim of our study is to demonstrate the relationship between the ABIC score and prognosis in BTC.
MATERIALS AND METHODS
In this study, a retrospective analysis was performed on 41 patients with non-metastatic BTC and 73 patients with metastatic BTC who were followed up in our clinic between 2003 and 2025. All patients were ≥18 years old at the time of diagnosis, and BTC was pathologically confirmed. The ABIC score was calculated separately for each group. A threshold value for the ABIC score was determined using Receiver Operating Characteristic (ROC) analysis, and based on this threshold, patients were divided into low and high ABIC score groups. Both the relationship between the ABIC score and prognosis and the other factors affecting prognosis were investigated.
RESULTS
In the non-metastatic BTC group, the cutoff value for the ABIC score was 6.89. The median survival time of patients with a high ABIC score was significantly shorter. In the metastatic BTC group, the cutoff value for the ABIC score was 7.41. Similarly, in this group, patients with a high ABIC score had a significantly shorter median survival time. Additionally, in the non-metastatic BTC group, tumor localization and stage were prognostic factors affecting survival, while in the metastatic BTC group, CEA and first-line chemotherapy were the prognostic factors influencing overall survival. We demonstrate that the ABIC score is a prognostic factor determining median survival in both non-metastatic and metastatic BTC patients.
引言
胆道癌（BTC）是一组异质性恶性肿瘤，包括胆囊癌、肝内胆管癌和肝外胆管癌。BTC预后的主要决定因素是疾病分期和根治性治疗的适用性。此外，肝功能也是影响胆道癌患者生存的因素之一。年龄-胆红素-国际标准化比值-肌酐（ABIC）评分先前已被证明可预测肝脏疾病的预后。我们研究的目的是证明ABIC评分与BTC预后之间的关系。
材料与方法
在本研究中，对2003年至2025年在我们诊所随访的41例非转移性BTC患者和73例转移性BTC患者进行了回顾性分析。所有患者在诊断时年龄≥18岁，且BTC经病理确诊。分别计算每组的ABIC评分。使用受试者工作特征（ROC）分析确定ABIC评分的阈值，并基于此阈值将患者分为ABIC评分低和高的组。研究了ABIC评分与预后之间的关系以及其他影响预后的因素。
结果
在非转移性BTC组中，ABIC评分的临界值为6.89。ABIC评分高的患者中位生存时间明显较短。在转移性BTC组中，ABIC评分的临界值为7.41。同样，在该组中，ABIC评分高的患者中位生存时间明显较短。此外，在非转移性BTC组中，肿瘤定位和分期是影响生存的预后因素，而在转移性BTC组中，癌胚抗原（CEA）和一线化疗是影响总生存的预后因素。我们证明ABIC评分是决定非转移性和转移性BTC患者中位生存的预后因素。
Zotero 插件